Australia markets closed

CORT Apr 2024 24.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.21000.0000 (0.00%)
As of 11:01AM EDT. Market open.
Full screen
Previous close1.2100
Open0.9000
Bid0.8000
Ask4.1000
Strike24.00
Expiry date2024-04-19
Day's range0.9000 - 1.3000
Contract rangeN/A
Volume16
Open interest357
  • Zacks

    Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

    The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

  • GlobeNewswire

    Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

    MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with

  • GlobeNewswire

    Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

    MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndrome (hypercortisolis